GO:0030228 lipoprotein particle receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0030228 (lipoprotein particle receptor activity) describes the molecular function of binding a lipoprotein particle and delivering it into the cell via endocytosis.
• The LDL receptor (LDLR) is the archetypal receptor for this activity and is central to plasma cholesterol homeostasis; its regulation is controlled at transcriptional and post-transcriptional levels.
• Receptor interactions control lipoprotein metabolism, including the clearance of VLDL, IDL, and LDL from circulation.
• The VLDL receptor (VLDLR) functions as a peripheral lipoprotein receptor with distinct tissue distribution and ligand specificity.
• Atherogenic LDL particles and impaired LDL uptake pathways contribute to cardiovascular disease and are increasingly linked to oncological processes.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable causal dissection of lipoprotein receptor genes in disease-relevant cell types.
Description
Lipoprotein particle receptor activity (GO:0030228) is a molecular function that enables a cell to bind a lipoprotein particle and internalize it through endocytosis. This activity is fundamental to lipid transport and cholesterol homeostasis, as it mediates the uptake of cholesterol-rich particles such as low-density lipoprotein (LDL) and very-low-density lipoprotein (VLDL) from the circulation. The receptor-ligand interactions that control lipoprotein metabolism are among the most studied in cardiovascular biology, and their dysregulation is a major driver of atherosclerosis and related disorders. Researchers study this activity to understand how cells acquire lipids, how plasma lipid levels are set, and how receptor dysfunction leads to disease. The function is defined not merely by ligand binding but by the delivery of the intact lipoprotein particle into the cell via endocytosis, distinguishing it from simple membrane association. This process requires specific receptor proteins that recognize apolipoprotein components of the particle and trigger internalization. Because lipoprotein uptake influences both normal physiology and pathological states ranging from cardiovascular disease to cancer, GO:0030228 is a key node for experimental modeling and therapeutic targeting.
lipoprotein particle receptor activity At A Glance
| GO ID | GO:0030228 |
|---|---|
| GO term | lipoprotein particle receptor activity |
| Ontology | molecular_function |
| Synonym | lipoprotein receptor activity; plasma lipoprotein particle receptor activity |
| Major function | Binding a lipoprotein particle and delivering it into the cell via endocytosis |
| Definition source | QuickGO |
| Example receptor | LDL receptor (LDLR) |
| Related process | Receptor-mediated endocytosis of lipoproteins |
| Disease relevance | Atherosclerosis, cardiovascular disease, cancer |
What Is GO:0030228?
In simple terms, lipoprotein particle receptor activity is the ability of a cell-surface receptor to grab a lipoprotein particle and pull it inside the cell. According to the QuickGO definition, this activity involves combining with a lipoprotein particle and delivering it into the cell via endocytosis. A lipoprotein particle is a clathrate complex in which lipids are enwrapped by proteins without covalent binding, creating a hydrophilic outer surface made of protein and the polar ends of phospholipids. This definition emphasizes two inseparable aspects: specific recognition of the lipoprotein particle and active endocytic delivery. Receptors with this activity, such as the LDL receptor, bind apolipoproteins on the particle surface and cluster into coated pits, leading to internalization. The activity is therefore not just binding but a complete uptake function that couples ligand recognition to membrane trafficking.
Why Is lipoprotein particle receptor activity Important in Cell Biology?
Lipoprotein particle receptor activity is essential for maintaining plasma lipid homeostasis and for supplying cells with cholesterol and fatty acids. The LDL receptor pathway is the primary route for clearing LDL from circulation, and its regulation directly impacts cardiovascular risk. Defects in this activity cause familial hypercholesterolemia and accelerate atherosclerosis. Beyond cardiovascular disease, impaired cholesterol and LDL uptake pathways are increasingly recognized in oncological diseases, where altered lipid metabolism supports tumor growth. Understanding this activity at the molecular level informs drug development, including statins and PCSK9 inhibitors, and provides a framework for studying receptor-ligand specificity. The VLDL receptor exemplifies how different receptors with this activity can have tissue-specific roles and distinct ligand preferences.
• Controls plasma cholesterol levels by mediating LDL clearance.
• Dysfunction leads to familial hypercholesterolemia and atherosclerosis.
• Provides cells with essential lipids for membrane synthesis and energy metabolism.
• VLDL receptor acts as a peripheral lipoprotein receptor with distinct functions.
• Implicated in cancer through altered cholesterol uptake pathways.
• Target for lipid-lowering therapies such as statins and PCSK9 inhibitors.
• Modeled in vitro using CRISPR knockout and knock-in cell lines.
• Receptor interactions determine lipoprotein metabolism and particle fate.
• Cyclosporin A-induced dyslipidemia involves LDLR-dependent and independent mechanisms.
• Apolipoprotein J (clusterin) shows lipid-associated properties relevant to lipoprotein interactions.
Mechanism, Genes and Research Methods
Ligand Recognition and Binding
In simple terms: The receptor first recognizes and binds a lipoprotein particle outside the cell.
Lipoprotein particle receptor activity begins with specific binding between a cell-surface receptor and a lipoprotein particle. The LDL receptor binds apolipoprotein B-100 on LDL and apolipoprotein E on remnant lipoproteins, a interaction that is calcium-dependent and involves the ligand-binding domain of the receptor. The VLDL receptor similarly binds apolipoprotein E-containing lipoproteins but with different tissue distribution and ligand preferences. Receptor interactions controlling lipoprotein metabolism depend on the apolipoprotein composition of the particle, which dictates which receptor will recognize it. This binding step is reversible and represents the specificity checkpoint of the activity.
Endocytic Delivery and Internalization
In simple terms: After binding, the receptor carries the lipoprotein particle into the cell through endocytosis.
Following ligand binding, the receptor-lipoprotein complex clusters in clathrin-coated pits and is internalized via endocytosis. This delivery step is a defining feature of GO:0030228, distinguishing it from mere binding activities. The internalized vesicle then fuses with endosomes, where the acidic environment causes the receptor to release its cargo. The receptor can then recycle back to the cell surface, while the lipoprotein particle is directed to lysosomes for degradation and release of cholesterol. This endocytic cycle is tightly regulated and is essential for maintaining cellular lipid homeostasis.
Receptor Recycling and Degradation
In simple terms: The receptor can be reused or destroyed, which controls how much uptake occurs.
After delivering its cargo, the LDL receptor typically recycles to the plasma membrane, allowing multiple rounds of uptake. The stability and recycling of the receptor are regulated by intracellular proteins such as PCSK9, which can bind the receptor and direct it to degradation instead of recycling. This regulation determines the number of active receptors on the cell surface and thus the overall capacity for lipoprotein particle receptor activity. Dysregulation of this step leads to altered plasma cholesterol levels and is a target of therapeutic intervention.
Regulation of Receptor Expression
In simple terms: Cells adjust how many receptors they make based on cholesterol needs.
The expression of genes encoding lipoprotein receptors is controlled by sterol-responsive transcription factors, primarily SREBP-2. When cellular cholesterol is low, SREBP-2 activates transcription of the LDLR gene, increasing receptor numbers and uptake activity. Conversely, high cholesterol suppresses this pathway. This feedback regulation ensures that lipoprotein particle receptor activity matches cellular demand. Additional layers of regulation include post-transcriptional mechanisms and protein stability, as reviewed in the context of LDL receptor regulation. The VLDL receptor is regulated differently and is not primarily responsive to sterol status, reflecting its distinct physiological role.
Lipoprotein Particle Structure and Receptor Fit
In simple terms: The lipoprotein particle's surface must match the receptor for uptake to occur.
A lipoprotein particle is a clathrate complex with a hydrophilic surface composed of apolipoproteins and polar phospholipid heads. The receptor recognizes specific apolipoproteins, such as apoB-100 or apoE, which are exposed on the particle surface. The lipid core, containing triglycerides and cholesteryl esters, is enwrapped by this protein-lipid shell without covalent bonds. This structural organization allows the particle to be soluble in plasma and to present ligands for receptor binding. Apolipoprotein J (clusterin) is an example of a lipid-associated apolipoprotein with functional and structural properties relevant to lipoprotein interactions.
Key Genes Involved in GO:0030228 lipoprotein particle receptor activity
The following genes encode receptors and associated proteins that carry out or regulate lipoprotein particle receptor activity.
| Gene | Major Role | Research Relevance |
|---|---|---|
| LDLR | Primary receptor for LDL uptake; binds apoB-100 and apoE | Central to cholesterol homeostasis and familial hypercholesterolemia |
| VLDLR | Peripheral lipoprotein receptor binding apoE-containing lipoproteins | Tissue-specific lipid uptake and signaling |
| LRP1 | Multifunctional endocytic receptor for apoE-containing lipoproteins | Lipoprotein metabolism and signaling |
| APOB | Major apolipoprotein of LDL; ligand for LDLR | Determines LDL particle recognition |
| APOE | Ligand for LDLR and VLDLR on remnant lipoproteins | Key regulator of lipoprotein clearance |
| PCSK9 | Binds LDLR and promotes its degradation | Therapeutic target for lowering LDL |
| SREBF2 | Transcription factor controlling LDLR expression | Master regulator of cholesterol uptake |
| SCARB1 | Scavenger receptor BI; mediates HDL cholesterol uptake | HDL metabolism and reverse cholesterol transport |
| CLU | Apolipoprotein J (clusterin); lipid-associated chaperone | Lipoprotein interactions and stress response |
| LDLRAP1 | Adaptor protein required for LDLR endocytosis | Autosomal recessive hypercholesterolemia |
| MYLIP | E3 ubiquitin ligase that degrades LDLR | Post-transcriptional regulation of LDLR |
| ABCA1 | Cholesterol efflux pump; affects lipoprotein particle formation | HDL biogenesis and reverse transport |
| ABCG1 | Cholesterol efflux pump to HDL | Cellular cholesterol homeostasis |
| CETP | Cholesteryl ester transfer protein; modifies lipoprotein composition | Lipoprotein remodeling and cardiovascular risk |
| LPL | Lipoprotein lipase; hydrolyzes triglycerides in lipoproteins | Generates ligands for receptor uptake |
| APOC3 | Apolipoprotein C-III; inhibits lipoprotein lipase | Triglyceride metabolism and cardiovascular risk |
| SORT1 | Sortilin; modulates VLDL secretion and LDL uptake | Genetic locus linked to LDL cholesterol |
How Is lipoprotein particle receptor activity Regulated?
Lipoprotein particle receptor activity is regulated at multiple levels. Transcriptional control by SREBP-2 adjusts LDLR expression according to cellular cholesterol status. Post-transcriptionally, PCSK9 binds the LDLR and redirects it to lysosomal degradation, reducing receptor recycling and uptake capacity. The E3 ubiquitin ligase MYLIP (IDOL) ubiquitinates LDLR and promotes its degradation, providing another layer of regulation. Hormonal and metabolic signals also influence receptor activity, as seen in cyclosporin A-induced dyslipidemia, which involves both LDLR-dependent and LDLR-independent mechanisms. The VLDL receptor is regulated differently, with tissue-specific expression patterns that are not primarily sterol-responsive. These regulatory mechanisms ensure that lipoprotein uptake matches physiological demand and can be targeted therapeutically.
lipoprotein particle receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LDLR | Familial hypercholesterolemia; atherosclerosis | LDLR knockout HepG2 cells; LDL uptake assay |
| PCSK9 | Hypercholesterolemia; cardiovascular risk | PCSK9 overexpression in hepatocytes; LDLR degradation assay |
| VLDLR | Peripheral lipid metabolism; possible neurological roles | VLDLR knockout cell lines; ligand binding assays |
| SCARB1 | HDL metabolism; reverse cholesterol transport | SCARB1 knockout macrophages; cholesterol efflux assay |
| CLU | Lipoprotein interactions; stress response | CLU knockout cells; lipid association studies |
Cardiovascular Disease and Atherosclerosis
Impaired lipoprotein particle receptor activity leads to elevated plasma LDL cholesterol, a major risk factor for atherosclerosis and cardiovascular disease. Defects in LDLR cause familial hypercholesterolemia, characterized by high LDL and premature coronary artery disease. Atherogenic LDL particles accumulate in the arterial wall and promote plaque formation. The receptor interactions that control lipoprotein metabolism are therefore central to cardiovascular pathology. Therapeutic strategies that enhance LDLR activity, such as statins and PCSK9 inhibitors, reduce cardiovascular events.
Cancer and Altered Lipid Uptake
Impaired cholesterol and LDL uptake pathways are increasingly implicated in oncological diseases. Cancer cells often require increased cholesterol for membrane synthesis and proliferation, and may upregulate lipoprotein uptake or scavenger receptor pathways. The LDL receptor and related family members can influence tumor growth and survival. Targeting lipoprotein particle receptor activity is being explored as a potential anticancer strategy, though normal tissue requirements must be considered.
Metabolic and Drug-Induced Dyslipidemia
Certain drugs and metabolic conditions alter lipoprotein receptor activity. Cyclosporin A induces dyslipidemia through both LDLR-dependent and LDLR-independent mechanisms, highlighting the interplay between receptor function and pharmacological intervention. The VLDL receptor may contribute to triglyceride-rich lipoprotein metabolism in peripheral tissues. Understanding these pathways helps predict and manage drug side effects and metabolic disorders.
From lipoprotein particle receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of LDLR abolish LDL uptake? | LDLR knockout cell line (e.g., HepG2) |
| Does a point mutation in the LDLR ligand-binding domain affect binding? | Point-mutation knock-in via CRISPR |
| Can a tagged LDLR be used to track endocytosis? | Tagged knock-in (e.g., GFP-LDLR) |
| Does overexpression of PCSK9 reduce LDLR levels? | PCSK9 overexpression cell line |
| Does VLDLR mediate uptake of apoE-rich lipoproteins? | VLDLR knockout and overexpression models |
| Does SCARB1 contribute to HDL cholesterol uptake? | SCARB1 knockout macrophages |
How to Study the lipoprotein particle receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Fluorescent LDL uptake assay | Binding and internalization of labeled LDL | Quantifying receptor activity in cells |
| CRISPR knockout screen | Genes required for lipoprotein uptake | Identifying novel regulators |
| RNA-seq | Transcriptional changes in receptor genes | Regulatory network analysis |
| Proteomics | Receptor protein abundance and modifications | Post-transcriptional regulation |
| Live-cell imaging | Receptor trafficking and recycling | Endocytic pathway dynamics |
| Western blot | Receptor protein levels | Validating knockout or overexpression |
| Flow cytometry | Cell surface receptor levels | Quantifying binding capacity |
| Ligand blot | Direct receptor-ligand interaction | Characterizing binding specificity |
Ligand Binding and Uptake Assays
Direct measurement of lipoprotein particle receptor activity uses fluorescently labeled LDL or VLDL incubated with cells, followed by flow cytometry or microscopy to quantify binding and internalization. These assays can distinguish surface-bound from internalized ligand using acid washes or quenching. They are essential for validating receptor function in knockout or mutant cell lines.
CRISPR-Based Genetic Screens
Genome-wide CRISPR knockout screens can identify genes required for lipoprotein uptake. Cells are transduced with a library, selected for altered LDL uptake using a fluorescent reporter, and sequenced to identify enriched sgRNAs. This approach has revealed both known and novel regulators of LDLR pathway.
Transcriptomic and Proteomic Profiling
RNA-seq and quantitative proteomics measure changes in expression of receptors and associated proteins under conditions that modulate lipoprotein uptake. These methods help define the regulatory network controlling GO:0030228. Proteomics can also assess receptor abundance and post-translational modifications.
Imaging and Trafficking Studies
Fluorescence microscopy and live-cell imaging track the endocytic trafficking of receptors and their lipoprotein cargo. Tagged receptors (e.g., GFP-LDLR) allow visualization of internalization and recycling. These techniques provide spatial and temporal resolution of the uptake process.
How CRISPR Can Be Used to Study GO:0030228 lipoprotein particle receptor activity
Knockout
CRISPR knockout of genes encoding lipoprotein receptors, such as LDLR or VLDLR, creates cell models with abolished uptake activity. These models are used to confirm the requirement for specific receptors in lipoprotein internalization and to study compensatory pathways. Knockout cells also serve as negative controls in uptake assays.
Point Mutation
Point mutations introduced by CRISPR base editing or homology-directed repair can mimic naturally occurring missense variants in receptor genes. These models help dissect the functional impact of specific residues on ligand binding or endocytosis. For example, mutations in the LDLR ligand-binding domain can be tested for their effect on LDL uptake.
Knock-in
Knock-in of tagged receptors (e.g., GFP or HA tags) allows visualization and biochemical isolation of receptor complexes. This approach is valuable for tracking receptor trafficking and interactions in live cells. Knock-in of disease-associated variants can also create isogenic models for studying pathogenesis.
Overexpression
Overexpression of wild-type or mutant receptors, or of regulatory proteins like PCSK9, is used to enhance or perturb lipoprotein particle receptor activity. Overexpression models help determine sufficiency and identify downstream effects on lipid metabolism. They are also used in drug screening to test modulators of uptake.
How EDITGENE Supports lipoprotein particle receptor activity Research
Researchers studying lipoprotein particle receptor activity-related genes often need to determine whether a candidate gene is causally involved in lipoprotein uptake, how specific mutations affect receptor function, and whether modulating its expression alters disease-relevant phenotypes. EDITGENE provides a comprehensive suite of CRISPR-based cell model services to address these questions with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for lipoprotein particle receptor activity research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| APOBR Knockout HEK293 Cell Line | EDJ-KQ51481 | Human | 55911 | Details Get a Quote |
| APOBR Knockout HeLa Cell Line | EDJ-KQ56653 | Human | 55911 | Details Get a Quote |
| APOBR Knockout A-549 Cell Line | EDJ-KQ65159 | Human | 55911 | Details Get a Quote |
| APOBR Knockout HCT 116 Cell Line | EDJ-KQ73595 | Human | 55911 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records
Frequently Asked Questions About lipoprotein particle receptor activity
What is lipoprotein particle receptor activity?
It is a molecular function (GO:0030228) where a receptor binds a lipoprotein particle and delivers it into the cell via endocytosis.
What genes are involved in lipoprotein particle receptor activity?
Key genes include LDLR, VLDLR, LRP1, APOB, APOE, PCSK9, and SREBF2, among others.
What is the role of the LDL receptor in cholesterol metabolism?
LDLR binds LDL and mediates its clearance from the bloodstream, controlling plasma cholesterol levels.
How is lipoprotein particle receptor activity regulated?
It is regulated by SREBP-2 transcription, PCSK9-mediated degradation, and other post-transcriptional mechanisms.
What diseases are associated with defective lipoprotein particle receptor activity?
Defects cause familial hypercholesterolemia, atherosclerosis, and are implicated in cancer and metabolic disorders.
What is the difference between LDLR and VLDLR?
LDLR primarily clears LDL, while VLDLR is a peripheral receptor with different tissue distribution and ligand preferences.
How can CRISPR be used to study lipoprotein particle receptor activity?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of receptor genes in uptake assays.
What methods measure lipoprotein particle receptor activity?
Fluorescent LDL uptake assays, flow cytometry, live-cell imaging, and CRISPR screens are commonly used.
Is lipoprotein particle receptor activity involved in cancer?
Yes, impaired cholesterol and LDL uptake pathways are increasingly linked to oncological diseases.
What is the GO ID for lipoprotein particle receptor activity?
The GO ID is GO:0030228.
Conclusion
Lipoprotein particle receptor activity (GO:0030228) is a fundamental molecular function that controls cellular lipid uptake and plasma lipoprotein metabolism. Its dysregulation underlies cardiovascular disease, metabolic disorders, and aspects of cancer biology. The LDL receptor and related family members serve as key models for understanding receptor-ligand specificity, endocytic trafficking, and regulation. CRISPR-based cell models provide powerful tools to dissect the causal roles of individual genes and variants in this activity. Continued research into GO:0030228 will inform therapeutic strategies for dyslipidemia and related diseases.
References
- 1. Schmidt HM et al.. 2025. Pathways and Molecular Mechanisms Governing LDL Receptor Regulation.. Circ Res 136(8):902-919 PMID: 40208925
- 2. Babiak J et al.. 1987. Lipoproteins and atherosclerosis.. Baillieres Clin Endocrinol Metab 1(3):515-50 PMID: 3330421
- 3. Calero M et al.. 1999. Functional and structural properties of lipid-associated apolipoprotein J (clusterin).. Biochem J 344 Pt 2(Pt 2):375-83 PMID: 10567218
- 4. Weisgraber KH et al.. 1985. Receptor interactions controlling lipoprotein metabolism.. Can J Biochem Cell Biol 63(8):898-905 PMID: 2998579
- 5. Hernando-Redondo J et al.. 2025. Atherogenic low-density lipoprotein and cardiovascular risk.. Curr Opin Lipidol 36(1):8-13 PMID: 39641158
- 6. Takahashi S et al.. 2004. The very low-density lipoprotein (VLDL) receptor: characterization and functions as a peripheral lipoprotein receptor.. J Atheroscler Thromb 11(4):200-8 PMID: 15356379
- 7. Solanelles Curco À et al.. 2025. Impaired cholesterol and LDL uptake pathways in the development of oncological and cardiovascular diseases.. Semin Cancer Biol 116:84-95 PMID: 40998097
- 8. Kockx M et al.. 2016. Low-Density Lipoprotein Receptor-Dependent and Low-Density Lipoprotein Receptor-Independent Mechanisms of Cyclosporin A-Induced Dyslipidemia.. Arterioscler Thromb Vasc Biol 36(7):1338-49 PMID: 27150391
